Oligomerix completed a Phase 1a safety study of OLX-07010, an oral tau self-association inhibitor, in 76 healthy volunteers across doses of 25–200 mg. The compound demonstrated a favorable safety profile and pharmacokinetic exposures consistent with efficacy thresholds observed in tau-mediated neurodegeneration models, supporting progression to Phase 1b patient studies.
Key Points
- Oral tau inhibitor showed favorable safety across single and multiple doses
- Serum exposures matched preclinical efficacy levels in animal models
- Results support advancement to Phase 1b studies in patient populations
Longevity Analysis
Tau aggregation represents a primary driver of cognitive decline and neurodegeneration in aging. An orally bioavailable small-molecule inhibitor that achieves systemic exposure at therapeutically relevant concentrations addresses a significant gap in addressing tau-mediated pathology—a process central to maintaining the structural and functional integrity of neurological circuits. Progression from healthy volunteer tolerability to patient-specific efficacy assessment marks a necessary intermediate step in translating bench observations into clinical outcomes affecting cognitive longevity.
Original published by Longevity.Technology.